Consolidated drug and chemical sales of Merck AG in Zug, Switzerland, rose 12% in 1991 to 2.18 billion Swiss francs ($1.44 billion). Operating profits improved 21% to 316 million francs ($209.0 million).
Taxes for 1991 were higher than the previous year (up 28%) and higher spending on restructuring in the UK meant that group net profits fell back 4% to 138 million francs ($91.3 million).
However, Merck was able to boost sales again in the first quarter of 1992 by about 10%, according to provisional figures, with pharmaceutical sales up 15% to 998 million francs ($660.1 million).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze